<DOC>
	<DOCNO>NCT02992704</DOCNO>
	<brief_summary>Chronic Hepatitis B carrier ( normal LFTs viral load &lt; 2 x 10^4 IU/ml recommend treat guideline low risk complication . However , unclear treatment enhance HBsAg loss show associate significantly low risk complication compare without HBsAg loss . Consequently , proof concept study determine possibility HBsAg loss Chronic Hepatitis B carrier randomise open label clinical trial compare treatment 24 week peg-interferon alpha 2a 48 week peginterferon alpha 2a ( randomise 1:1:1 ) . The primary endpoint HBsAg loss evaluate 24 week end therapy therapy match equivalent timepoint control arm . The sample size calculation 30 patient arm 20 % difference experimental arm control arm .</brief_summary>
	<brief_title>PEG-INTERFERON FOR INACTIVE HBV CARRIERS</brief_title>
	<detailed_description>1 . Hypothesis : Chronic hepatitis B carrier ( define HBeAg negative hepatitis B patient HBV DNA &lt; 2x104 IU/mL , absence cirrhosis normal ALT ) may experience high rate HBsAg seroclearance pegylated interferon therapy . 2A . Primary Objective - The proportion subject HBsAg loss Week 24 followup treatment 24 48 week pegylated interferon alpha 2a compare therapy . 2B . Secondary Objective - The proportion subject experience HBsAg loss 24 versus 48 week pegylated interferon end treatment , end followup . - The rate quantitative HBsAg decline relation HBsAg loss - The proportion subject virological response ( HBV DNA level &lt; 13.5IU/mL ) Weeks 12 24 treatment , week 24 followup . 2C Study population : 90 patient enrol . 3.1 Inclusion Criteria For entry study , follow inclusion criterion must meet : - Males female age 21-75 year old ( inclusive ) - Treatment naïve - Documented HBsAg HBV DNA positive ≥ 6 month . - Documented HBeAg negative anti-HBe positive - ALT ≤1xULN - quantitative HBsAg &lt; 1,000 IU/ml - HBV DNA &lt; 2x104 IU/mL screen - Absence cirrhosis document liver biopsy transient elastography within 6 month ( Fibroscan® ; Fibrosis stage &gt; 2 ( score ≥ 10Kpa ) eligible study . ) - Patient agree take investigational drug systemic anti-viral , cytotoxic , corticosteroid , immunomodulatory agent Chinese traditional remedy unless clinically indicate . - Patient able give write consent prior study start comply study requirement . - Women childbearing age must negative urine ( ß-HCG ) pregnancy test take within 14 day start therapy 3.2 Exclusion Criteria For entry study , follow exclusion criterion must meet : - Patients currently treatment nucleoside/nucleotide analogue treat Hepatitis B past - Presence cirrhosis document liver biopsy transient elastography ( score ≥ 10kpa ) - Active Co-infection HIV antibody , HCV antibody HDV antibody positivity . - Evidence decompensated liver disease define direct ( conjugate ) bilirubin &gt; 1.2x upper limit normal ( ULN ) , prothrombin time ( PT ) &gt; 1.5xULN , serum bilirubin &lt; 35g/L , prior history clinical hepatic decompensation illustrate presence ( eg . ascites , encephalopathy , variceal haemorrhage ) - Evidence hepatocellular carcinoma - Absolute neutrophil count &lt; 1.5x10^9/L Hemoglobin &lt; 12 g/L men &lt; 11 g/L woman , platelet count &lt; 90x10^9/L - History depression psychiatric disease - Uncontrolled thyroid disease define thyroid-stimulating hormone ( TSH ) &gt; 1.2 ULN 0.8xLLN thyroid dysfunction - Any immunomodulators , systemic cytotoxic agent , systemic cortiosteriods within 6 month trial entry - Significant renal , cardiovascular , pulmonary , neurological , autoimmune disease bone disease ( e.g. , osteomalacia , chronic osteomyelitis , osteogenesis imperfecta , osteochrondroses , multiple bone fracture ) - Malignant disease within 5 year trial entry - Women pregnant practice adequate birth control measure , ( define two method birth control least one barrier method ) lactating . 4.1 Study Treatment Product , Dose , Mode Administration : Peginterferon α-2a ( PEG ) , 180mcg , administer weekly subcutaneous injection specify period time ( see Study Design , Arms B C ) . Pegasys® ( Roche Pharmaceuticals ) . Reference Therapy , Dose , Mode Administration : Peginterferon α-2a ( PEG ) , 180mcg subcutaneous injection weekly 4.2 Method Assigning Subjects Treatment Randomisation perform computer generate random code ( perform Singapore Clinical Research Institute ) mask allocation sequence . 4.3 Blinding/Unblinding There blind therapy study conduct open label study standard interferon clinical trial . 5 . Study Assessments procedures 5.1 Time Event schedule 5.1.1 . Screening Visit ( Days - 45 1 ) 5.1.2 . Baseline Assessments ( day 1 ) 5.1.3 . Treatment Assessments ( day 2 week 48 ) 5.1.4 . Peginterferon-free Follow-up ( FU ) Visits : FU-Week 1 24 5.2 Clinical Laboratory Tests Hematology : Full blood count ( FBC ) ; Chemistry : Sodium , potassium , creatinine , albumin , alkaline phosphatase , aspartate transaminase , alanine transaminase , lactate dehydrogenase , total bilirubin , creatinine phosphokinase , alphafetoprotein , ( thyroid stimulate hormone free T4 patient pegylated interferon alpha 2a ) ; Urinalysis : Protein , Blood , Glucose ; Viral serology : HBsAg , qHBsAg anti-HBs 6.0 Efficacy assessment : HBsAg qualitative HBsAg quantitative HBV DNA ( real time PCR )</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Treatment naïve Documented HBsAg HBV DNA positive ≥ 6 month . Documented HBeAg negative antiHBe positive ALT ≤1xULN quantitative HBsAg &lt; 1,000 IU/ml HBV DNA &lt; 2x104 IU/mL screen Absence cirrhosis document liver biopsy transient elastography within 6 month ( Fibroscan® ; Fibrosis stage &gt; 2 ( score ≥ 10Kpa ) eligible study . ) Patient agree take investigational drug systemic antiviral , cytotoxic , corticosteroid , immunomodulatory agent Chinese traditional remedy unless clinically indicate . Patient able give write consent prior study start comply study requirement . Women childbearing age must negative urine ( ßHCG ) pregnancy test take within 14 day start therapy Patients currently treatment nucleoside/nucleotide analogue treat Hepatitis B past Presence cirrhosis document liver biopsy transient elastography ( score ≥ 10kpa ) Active Coinfection HIV antibody , HCV antibody HDV antibody positivity . Evidence decompensated liver disease define direct ( conjugate ) bilirubin &gt; 1.2x upper limit normal ( ULN ) , prothrombin time ( PT ) &gt; 1.5xULN , serum bilirubin &lt; 35g/L , prior history clinical hepatic decompensation illustrate presence ( eg . ascites , encephalopathy , variceal haemorrhage ) Evidence hepatocellular carcinoma Absolute neutrophil count &lt; 1.5x10^9/L Hemoglobin &lt; 12 g/L men &lt; 11 g/L woman , platelet count &lt; 90x10^9/L History depression psychiatric disease Uncontrolled thyroid disease define thyroidstimulating hormone ( TSH ) &gt; 1.2 ULN 0.8xLLN thyroid dysfunction Any immunomodulators , systemic cytotoxic agent , systemic cortiosteriods within 6 month trial entry Significant renal , cardiovascular , pulmonary , neurological , autoimmune disease bone disease ( e.g. , osteomalacia , chronic osteomyelitis , osteogenesis imperfecta , osteochrondroses , multiple bone fracture ) Malignant disease within 5 year trial entry Women pregnant practice adequate birth control measure , ( define two method birth control least one barrier method ) lactating .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>